Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 10/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.36 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 5/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10243404 | 0.74 | KDM4E (0.34) | KDM4E | |
| SCHEMBL335056 | 0.74 | KCNA5 (0.44) | KCNA5KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL335078 | 0.73 | CXCR4 (0.32) | CXCR4CYP2D6KCNA5KCNE1CHRM1 | |
| SCHEMBL334298 | 0.72 | SMN1; SMN2 (0.34) | CYP2D6KCNA5KCNE1SMN1; SMN2 | |
| SCHEMBL335194 | 0.70 | CYP1A2 (0.39) | CYP2D6 | |
| SCHEMBL1132541 | 0.70 | CYP1A2 (0.36) | CYP2D6 | |
| SCHEMBL335843 | 0.70 | CYP2D6 (0.36) | CYP2D6HRH1KCNH2CHRM1 | |
| SCHEMBL294332 | 0.66 | RAB9A (0.41) | CYP2D6HRH1KCNH2CHRM1POLB | |
| SCHEMBL10115951 | 0.66 | RAB9A (0.41) | CYP2D6HRH1KCNH2CHRM1POLB | |
| SCHEMBL12694263 | 0.66 | RAB9A (0.41) | CYP2D6HRH1KCNH2CHRM1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | CXCR4 1537/4885CYP2D6 1574/4885KCNA5 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.